US EditionPublished • loading... • Updated
‘Next generation’ leukaemia drug approved on NHS
Obe-cel, a UK-developed CAR T-cell therapy, offers 77% remission in trials and fewer side effects for adults with relapsed B-cell acute lymphoblastic leukaemia.
- A 'next generation' immunotherapy treatment called obe-cel, developed by the University College London spinout company Autolus, has the potential to cure leukaemia and has been approved for use in the NHS for those aged 26 and over.
- Obe-Cel is a type of CAR T-cell therapy that genetically modifies cells to enable the body's own immune system to recognise and attack cancer, and only needs to be given once in a lifetime.
- The National Institute for Health and Care Excellence has recommended obe-cel, stating that it could help more than 150 people over the next three years who have relapsed or refractory B-cell acute lymphoblastic leukaemia.
Insights by Ground AI
15 Articles
15 Articles
‘Next generation’ treatment to cure leukaemia given NHS approval
The therapy was developed by Autolus, a University College London spinout company. A “next generation” immunotherapy treatment that has the potential to cure leukaemia has been given NHS approval. Obe-cel is a type of CAR T-cell therapy developed in the UK and works by genetically modifying cells to enable the body’s own immune system to recognise and attack cancer. The therapy, which only needs to be given once in a lifetime, was developed by A…
Coverage Details
Total News Sources15
Leaning Left3Leaning Right1Center6Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 30%
C 60%
Factuality
To view factuality data please Upgrade to Premium
